| Identification | Back Directory | [Name]
Spartalizumab | [CAS]
1935694-88-4 | [Synonyms]
Spartalizumab
Spartalizumab (anti-PD-1)
Research Grade Spartalizumab
Research Grade Spartalizumab (DHH02214) |
| Hazard Information | Back Directory | [Uses]
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC)[1]. | [References]
[1] Jaume Capdevila, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020 Aug 10;38(23):2620-2627. DOI:10.1200/JCO.19.02727 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|